Heartburn Medication Recall 2019: More Ranitidine Medications Recalled For Cancer-Causing Impurity

After a series of recalls for heartburn medications, such as Zantac, and a number of retailers pulling the product from their shelves, Aurobindo Pharma USA (AUROPHARMA.NS) has recalled 38 lots of ranitidine heartburn medication and syrups because they may contain a cancer-causing ingredient.

The recalled medication includes one lot of ranitidine tablets, 150 mg and 37 lots of ranitidine capsules, 150 and 300 mg, and ranitidine syrup, 15 mg/mL, because of the detection of N-nitrosodimethylamine (NDMA) – a cancer-causing impurity.

Ranitidine is used in the treatment of heartburn related to acid indigestion and sour stomach that is brought on by eating or drinking certain foods. The recalled medication was distributed nationwide from Sept. 28, 2018, to Sept. 19.

A full list of recalled medications can be viewed here. The product name, manufacturer details, and batch or lot number is located on the bottle of the medication.

Questions about the recall or to report an adverse effect from the medication can be directed to Aurobindo Pharma at 1-866-850-2876, Option 2, or by emailing pvg@aurobindousa.com. Questions about returning the affected medication can be directed to Qualanex at 1-888-504-2014, Monday through Friday, from 7 a.m. to 4 p.m. CST or by email at recall@qualanex.com.

Consumers that are taking the recalled medication should contact their healthcare provider or pharmacist for an alternative treatment plan. Patients that experience problems from taking the affected heartburn medication should see their physician.

Aurobindo Pharma has not received any reports of adverse reactions due to the recalled medication.

Shares of Aurobindo Pharma stock were down 2.67% as of 10:23 a.m. EST on Friday.